PTPRC and Miyoshi myopathy: Importantly, in the BR baseline group compared to the similar GR group, there was a higher tumor burden with high expression of classical MM markers, namely, CD38 and CD56 (NCAM), accompanied by the absence of CD45 expression (Figure 3F).